Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice.
The glycine B receptor partial agonists L 687,414, D-cycloserine and (+)-HA 966, and the glycine B receptor antagonists MDL 29,951 and 5,7-dichloro-2,4 dihydroxy-3-phenyl-quinoline dione (DCPQ) dose-dependently inhibited the late phase (LP) of formalin-induced licking (FIL) elicited by intraplantar formalin in mice at doses exerting little motor disruption in the rotarod test. In distinction, the early phase (EP) of FIL and the writhing response to intra-abdominal acetic acid were little influenced and, irrespective of stimulus intensity, they failed to modify the tail-flick response to phasic, thermal or mechanical stimulation of the tail. In contrast to glycine B ligands, competitive antagonists at the NMDA receptor recognition site (CPP, CGS 19755, CGP 34879 and 39551) and blockers of the associated ion channel ((+)-MK 801, (-)-MK 801, memantine and ketamine) all blocked both the LP and EP of FIL and induced ataxia at comparable doses. In conclusion, normalization of transmission at NMDA receptors by inhibition of the coupled glycine B site preferentially elicits antinociception against prolonged (chemical) noxious stimulation in the absence of a marked influence upon motor coordination.
Millan
M J
MJ
Department of Psychopharmacology, Centre de Recherches de Croissy, Paris, France.
Seguin
L
L
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000494:pharmacology; D000085:Acetates; D019342:Acetic Acid; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D003523:Cycloserine / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005557:Formaldehyde; D007211:Indoles / Q000494:pharmacology; D008024:Ligands; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D011422:Propionates / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology*; D018009:Receptors, Glycine / Q000819:agonists* / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists* / Q000037:antagonists & inhibitors
C000588735:2-carboxy-4,6-dichloro-(1H)-indole-3-propanoic acid; C091322:5,7-dichloro-2,4-dihydroxy-3-phenylquinolinedione; D000085:Acetates; D000927:Anticonvulsants; D007211:Indoles; D008024:Ligands; D011422:Propionates; D011760:Pyrrolidinones; D015363:Quinolones; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C064540:CGP 39551; C084173:L 687414; D005557:Formaldehyde; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate; D003523:Cycloserine; C001369:1-hydroxy-3-amino-2-pyrrolidone; D019342:Acetic Acid